Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06450873 · ClinicalTrials.gov registry record · Phase 2
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
A Phase 2 study of HER2-Negative Breast Carcinoma and Estrogen Receptor-Positive Breast Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06450873 is a Phase 2 study of HER2-Negative Breast Carcinoma and Estrogen Receptor-Positive Breast Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 430-participant average among 18 other HER2-Negative Breast Carcinoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06450873, a Phase 2 study of HER2-Negative Breast Carcinoma and Estrogen Receptor-Positive Breast Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous evidence of significant tumor shrinkage occurring in the 2-month window between diagnosis and surgery in women who have taken TTM. Giving TTM may be effective in treating post-menopausal women with HER2-negative, ER-positive breast cancer undergoing surgery.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Coriolus Versicolor Extract
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06450873
The ClinicalTrials.gov registry entry for NCT06450873 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 430-participant average among 18 other HER2-Negative Breast Carcinoma trials with a reported enrollment target (91% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HER2-Negative Breast Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Questionnaire Administration is the first listed.
NCT06450873 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06450873 about?
NCT06450873 is a clinical study titled "Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery". This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins...
What is the current status of trial NCT06450873?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-10-25. Estimated completion is 2028-04-30.
What conditions does trial NCT06450873 study?
This clinical trial studies the following conditions: HER2-Negative Breast Carcinoma, Estrogen Receptor-Positive Breast Carcinoma.
What interventions are being tested in trial NCT06450873?
The interventions under investigation include: Questionnaire Administration (OTHER), Coriolus Versicolor Extract (DRUG).
Who is sponsoring clinical trial NCT06450873?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06450873 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-Negative Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
RECRUITING · Phase 2
-
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
RECRUITING · Phase 2
-
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
RECRUITING · Phase 2
-
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
RECRUITING · Phase 3
-
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
RECRUITING · NA
-
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
RECRUITING · NA
Explore more on PlainTrial
HER2-Negative Breast Carcinoma
All registered trials for this condition
Estrogen Receptor-Positive Breast Carcinoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.